These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 38321065)

  • 21. Functional Exhaustion of HBV-Specific CD8 T Cells Impedes PD-L1 Blockade Efficacy in Chronic HBV Infection.
    Ferrando-Martinez S; Snell Bennett A; Lino E; Gehring AJ; Feld J; Janssen HLA; Robbins SH
    Front Immunol; 2021; 12():648420. PubMed ID: 34589081
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Stromal PD-L1-Positive Regulatory T cells and PD-1-Positive CD8-Positive T cells Define the Response of Different Subsets of Non-Small Cell Lung Cancer to PD-1/PD-L1 Blockade Immunotherapy.
    Wu SP; Liao RQ; Tu HY; Wang WJ; Dong ZY; Huang SM; Guo WB; Gou LY; Sun HW; Zhang Q; Xie Z; Yan LX; Su J; Yang JJ; Zhong WZ; Zhang XC; Wu YL
    J Thorac Oncol; 2018 Apr; 13(4):521-532. PubMed ID: 29269008
    [TBL] [Abstract][Full Text] [Related]  

  • 23. T antigen-specific CD8+ T cells associate with PD-1 blockade response in virus-positive Merkel cell carcinoma.
    Hansen UK; Church CD; Carnaz Simões AM; Frej MS; Bentzen AK; Tvingsholm SA; Becker JC; Fling SP; Ramchurren N; Topalian SL; Nghiem PT; Hadrup SR
    J Clin Invest; 2024 Jan; 134(8):. PubMed ID: 38618958
    [TBL] [Abstract][Full Text] [Related]  

  • 24. IFN-γ-dependent interactions between tissue-intrinsic γδ T cells and tissue-infiltrating CD8 T cells limit allergic contact dermatitis.
    Muñoz-Ruiz M; Llorian M; D'Antuono R; Pavlova A; Mavrigiannaki AM; McKenzie D; García-Cassani B; Iannitto ML; Wu Y; Dart R; Davies D; Jamal-Hanjani M; Jandke A; Ushakov DS; Hayday AC
    J Allergy Clin Immunol; 2023 Dec; 152(6):1520-1540. PubMed ID: 37562754
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Rescue therapy for patients with anti-PD-1-refractory Merkel cell carcinoma: a multicenter, retrospective case series.
    LoPiccolo J; Schollenberger MD; Dakhil S; Rosner S; Ali O; Sharfman WH; Silk AW; Bhatia S; Lipson EJ
    J Immunother Cancer; 2019 Jul; 7(1):170. PubMed ID: 31287031
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Association of Merkel Cell Polyomavirus Status With p53, RB1, and PD-L1 Expression and Patient Prognosis in Merkel Cell Carcinomas: Clinical, Morphologic, and Immunohistochemical Evaluation of 17 Cases.
    Öğüt B; Bayram EK; İnan MA; Kestel S; Erdem Ö
    Appl Immunohistochem Mol Morphol; 2023 Jul; 31(6):371-378. PubMed ID: 37126387
    [TBL] [Abstract][Full Text] [Related]  

  • 27. CD4
    Xiao M; Xie L; Cao G; Lei S; Wang P; Wei Z; Luo Y; Fang J; Yang X; Huang Q; Xu L; Guo J; Wen S; Wang Z; Wu Q; Tang J; Wang L; Chen X; Chen C; Zhang Y; Yao W; Ye J; He R; Huang J; Ye L
    J Immunother Cancer; 2022 May; 10(5):. PubMed ID: 35580929
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Human Vγ9Vδ2 T cells exert anti-tumor activity independently of PD-L1 expression in tumor cells.
    Tomogane M; Sano Y; Shimizu D; Shimizu T; Miyashita M; Toda Y; Hosogi S; Tanaka Y; Kimura S; Ashihara E
    Biochem Biophys Res Commun; 2021 Oct; 573():132-139. PubMed ID: 34407491
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Merkel cell carcinoma showing regression after biopsy: Evaluation of programmed cell death 1-positive cells.
    Fujimoto N; Nakanishi G; Kabuto M; Nakano T; Eto H; Nakajima H; Sano S; Tanaka T
    J Dermatol; 2015 May; 42(5):496-9. PubMed ID: 25708589
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Exhausted intratumoral Vδ2
    Rancan C; Arias-Badia M; Dogra P; Chen B; Aran D; Yang H; Luong D; Ilano A; Li J; Chang H; Kwek SS; Zhang L; Lanier LL; Meng MV; Farber DL; Fong L
    Nat Immunol; 2023 Apr; 24(4):612-624. PubMed ID: 36928415
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Merkel Cell Carcinoma and Immune Evasion: Merkel Cell Polyomavirus Small T-Antigen‒Induced Surface Changes Can Be Reverted by Therapeutic Intervention.
    Schlemeyer T; Ohnezeit D; Virdi S; Körner C; Weißelberg S; Starzonek S; Schumacher U; Grundhoff A; Indenbirken D; Albertini S; Fischer N
    J Invest Dermatol; 2022 Nov; 142(11):3071-3081.e13. PubMed ID: 35636504
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Programmed death receptor-1/programmed death receptor ligand-1 blockade after transient lymphodepletion to treat myeloma.
    Kearl TJ; Jing W; Gershan JA; Johnson BD
    J Immunol; 2013 Jun; 190(11):5620-8. PubMed ID: 23616570
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Co-expression of NGF and PD-L1 on tumor-associated immune cells in the microenvironment of Merkel cell carcinoma.
    Wehkamp U; Stern S; Krüger S; Weichenthal M; Hauschild A; Röcken C; Egberts F
    J Cancer Res Clin Oncol; 2018 Jul; 144(7):1301-1308. PubMed ID: 29744662
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Immunotherapy for Merkel Cell Carcinoma.
    Nagase K; Narisawa Y
    Curr Treat Options Oncol; 2018 Sep; 19(11):57. PubMed ID: 30238195
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Indirect Impact of PD-1/PD-L1 Blockade on a Murine Model of NK Cell Exhaustion.
    Alvarez M; Simonetta F; Baker J; Morrison AR; Wenokur AS; Pierini A; Berraondo P; Negrin RS
    Front Immunol; 2020; 11():7. PubMed ID: 32117218
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Combination immunotherapy with interleukin-2 surface-modified tumor cell vaccine and programmed death receptor-1 blockade against renal cell carcinoma.
    Zhang X; Shi X; Li J; Hu Z; Gao J; Wu S; Long Z
    Cancer Sci; 2019 Jan; 110(1):31-39. PubMed ID: 30343514
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Immune Checkpoint Markers in Superficial Angiosarcomas: PD-L1, PD-1, CD8, LAG-3, and Tumor-Infiltrating Lymphocytes.
    Googe PB; Flores K; Jenkins F; Merritt B; Moschos SJ; Grilley-Olson JE
    Am J Dermatopathol; 2021 Aug; 43(8):556-559. PubMed ID: 33156018
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The prognostic significance of PD-L1 expression on tumor and immune cells in Merkel cell carcinoma.
    Guénolé M; Bénigni P; Bourbonne V; Lucia F; Legoupil D; Pradier O; Misery L; Uguen A; Schick U
    J Cancer Res Clin Oncol; 2021 Sep; 147(9):2569-2578. PubMed ID: 34115240
    [TBL] [Abstract][Full Text] [Related]  

  • 39. PD-1-expressing B cells suppress CD4
    Wang X; Wang G; Wang Z; Liu B; Han N; Li J; Lu C; Liu X; Zhang Q; Yang Q; Wang G
    Mol Immunol; 2019 May; 109():20-26. PubMed ID: 30851633
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Dual blockade of PD-1 and CTLA-4 combined with tumor vaccine effectively restores T-cell rejection function in tumors.
    Duraiswamy J; Kaluza KM; Freeman GJ; Coukos G
    Cancer Res; 2013 Jun; 73(12):3591-603. PubMed ID: 23633484
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.